Quotes 5-day view Delayed Nasdaq
06/28/2022
06/29/2022
06/30/2022
07/01/2022
07/05/2022
Date
1.82(c)
1.79(c)
1.73(c)
1.89(c)
2.07
Last
5 567 759
6 150 239
5 739 539
6 026 868
8 077 022
Volume
-6.67%
-1.65%
-3.35%
+9.25%
+9.52%
Change
Estimated financial data (e) (USD)
Sales 2022
1,81 M
-
-
Net income 2022
-263 M
-
-
Net Debt 2022
-
-
-
P/E ratio 2022
-1,77x
Yield 2022
-
Sales 2023
23,9 M
-
-
Net income 2023
-245 M
-
-
Net Debt 2023
-
-
-
P/E ratio 2023
-2,11x
Yield 2023
-
Capitalization
433 M
433 M
-
Capi. / Sales 2022
239x
Capi. / Sales 2023
18,1x
Nbr of Employees
317
Free-Float
98,3%
Inovio Pharmaceuticals, Inc. (INOVIO) is a biotechnology company. The Company is focused on bringing to market designed deoxyribonucleic acid (DNA) medicines and vaccines to help protect people from infectious diseases, including COVID-19, and to help treat people with cancer, and conditions associated with human papillomavirus (HPV). Its DNA medicines pipeline consists of three types of product candidates, namely...
Ratings of Inovio Pharmaceuticals, Inc.
All news about INOVIO PHARMACEUTICALS, INC.
07/01 INOVIO Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR
06/27 INOVIO Appoints Dr. Michael Sumner, MB BS, MBA as Chief Medical Officer PR
06/24 INOVIO PHARMACEUTICALS, INC.(NASDAQG : INO) added to Russell 3000E Value IndexCI
06/24 INOVIO PHARMACEUTICALS, INC.(NASDAQG : INO) added to Russell Microcap Value IndexCI
06/24 INOVIO PHARMACEUTICALS, INC.(NASDAQG : INO) added to Russell 3000E IndexCI
06/24 INOVIO PHARMACEUTICALS, INC.(NASDAQG : INO) added to Russell Microcap IndexCI
05/27 Inovio Pharmaceuticals Says Brain Cancer Combination Therapy Produced Immune Response i.. MT
05/27 INOVIO Announces Survival Results for INO-5401 + INO-9012 in Combination with Libtayo(R.. CI
05/25 Biotech Recovery Accelerates These Companies Benefit (IPA, SIGA, MNKD, INO, CTIC) AQ
05/23 INOVIO to Present at Jefferies 2022 Healthcare Conference PR
05/17 INOVIO PHARMACEUTICALS, INC. : Change in Directors or Principal Officers, Submission of Ma..AQ
05/11 Oppenheimer Downgrades Inovio Pharmaceuticals to Perform From Outperform, Removes $30 P.. MT
05/10 Inovio to discontinue COVID vaccine trial, appoints Jacqueline Shea as CEO RE
05/10 INOVIO PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, Change in Di..AQ
05/10 INOVIO : Q1 Earnings SnapshotAQ
News in other languages on INOVIO PHARMACEUTICALS, INC.
Analyst Recommendations on INOVIO PHARMACEUTICALS, INC.
Chart INOVIO PHARMACEUTICALS, INC.
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends INOVIO PHARMACEUTICALS, INC.
Short Term Mid-Term Long Term Trends Bullish Bearish Bearish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
HOLD
Number of Analysts
7
Last Close Price
2,07 $
Average target price
5,00 $
Spread / Average Target
142%
Please enable JavaScript in your browser's settings to use dynamic charts.